Jonathan D. Pollock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jonathan D. Pollock has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
A. Roger Little
National Institute on Drug Abuse/NIH
3 shared publicationsDa-Yu Wu
Division of Basic Neurobiology and Behavioral Research, Genetics and Molecular Neurobiology Research Branch, National Institute on Drug Abuse/National Institutes of Health (NIH), 6001 Executive Boulevard, Bethesda, MD 20850, USA
2 shared publicationsWilson M. Compton
National Institute on Drug Abuse, National Institutes of Health, Bethesda, Maryland
2 shared publications- A. Roger Little
National Institute on Drug Abuse/NIH
1 shared publication Allison Hoffman
1 shared publicationAmy C. Lossie
National Institute on Drug Abuse/NIH
1 shared publication
Latest Publications
- Open Access
- 8 July 2023
- Published by Elsevier in Addiction Neuroscience
- Vol. 8
Editorial - Advancing Biomarkers for Treatment of Smoking and Nicotine Dependence: An Overview
- 8 July 2023
- Published by Elsevier in Addiction Neuroscience
- Vol. 8
Open AccessEditorial - Advancing Biomarkers for Treatment of Smoking and Nicotine Dependence: An Overview
- 18 October 2022
- Published by Springer Nature
- p. 3153-3200
Revolution in Genetics
- Open Access
- 22 June 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (6) , e2218094
Analysis of Access to Prescription Data Management Programs Data for Research
In response to the ongoing opioid crisis,1-3 50 states and 4 territories (Puerto Rico, District of Columbia, Northern Mariana Islands, and Guam) enacted prescription drug monitoring programs (PDMPs) to reduce risky prescribing of opioids by health care practitioners, decrease misuse of controlled substances, and decrease overdose deaths. Although health care practitioners can access PDMP data for clinical purposes through online information-sharing hubs such as PMPGateway and RxCheck, policies for access to PDMP data and linking of PDMP data to other data for research purposes are unclear for many jurisdictions. PDMP data have been used to evaluate high-risk use and prescribing practices, to improve data quality, to determine health outcomes, and to predict opioid overdose.4-6 Linking of PDMP data to electronic health records and other data has the potential for repurposing medications to treat pain and addiction, for identifying comorbid health conditions, for identifying genetic variants associated with addiction, and for determining how to best target resources and interventions to address opioid misuse. The objective of the current cross-sectional study is to determine the availability of PDMP data for research and whether PDMP data can be linked to other data.
- 22 June 2022
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 5 (6) , e2218094
Open AccessAnalysis of Access to Prescription Data Management Programs Data for Research
In response to the ongoing opioid crisis,1-3 50 states and 4 territories (Puerto Rico, District of Columbia, Northern Mariana Islands, and Guam) enacted prescription drug monitoring programs (PDMPs) to reduce risky prescribing of opioids by health care practitioners, decrease misuse of controlled substances, and decrease overdose deaths. Although health care practitioners can access PDMP data for clinical purposes through online information-sharing hubs such as PMPGateway and RxCheck, policies for access to PDMP data and linking of PDMP data to other data for research purposes are unclear for many jurisdictions. PDMP data have been used to evaluate high-risk use and prescribing practices, to improve data quality, to determine health outcomes, and to predict opioid overdose.4-6 Linking of PDMP data to electronic health records and other data has the potential for repurposing medications to treat pain and addiction, for identifying comorbid health conditions, for identifying genetic variants associated with addiction, and for determining how to best target resources and interventions to address opioid misuse. The objective of the current cross-sectional study is to determine the availability of PDMP data for research and whether PDMP data can be linked to other data.
- 1 January 2021
- Published by Springer Nature
- p. 1-48
Revolution in Genetics
- 27 October 2016
- Published by Springer Nature
- p. 2793-2835
The Revolution in Genetic Sequencing and Analysis
- 27 October 2016
- Published by Springer Nature
- p. 2793-2835
The Revolution in Genetic Sequencing and Analysis
- 1 January 2015
- Published by Springer Nature
- p. 1-43
The Revolution in Genetic Sequencing and Analysis
- Open Access
- 1 January 2014
- Published by Elsevier in Trends in Neurosciences
- Vol. 37 (2) , 106-123
Molecular neuroanatomy: a generation of progress
- 1 January 2014
- Published by Elsevier in Trends in Neurosciences
- Vol. 37 (2) , 106-123
Open AccessMolecular neuroanatomy: a generation of progress
- Open Access
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 3, 34843
Bioinformatic Challenges of Big Data in Non-Coding RNA Research
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 3, 34843
Open AccessBioinformatic Challenges of Big Data in Non-Coding RNA Research
- 1 August 2009
- Published by Elsevier in The Lancet
- Vol. 374 (9689) , 513-514
Treatments for nicotine addiction should be a top priority
- 1 August 2009
- Published by Elsevier in The Lancet
- Vol. 374 (9689) , 513-514
Treatments for nicotine addiction should be a top priority